Maria Lattanzi

2.2k citations

37 papers · 1.6k indexed · 1 hit paper · h-index 19

Aging top 1%
Epidemiology top 5%
- Influenza Virus Research Studies 18
- Respiratory viral infections research 14
- Pneumonia and Respiratory Infections 7
Infectious Diseases top 5%
- SARS-CoV-2 and COVID-19 Research 9
Immunology top 5%
- Immune Response and Inflammation 4
Microbiology top 5%
- Bacterial Infections and Vaccines 4
Public Health, Environmental and Occupational Health
- Streptococcal Infections and Treatments 4
- Mosquito-borne diseases and control 3

Co-authors: Giuseppe Del Giudice Anne Katrin Hilbert Jens Præstgaard Nicholas M. Valiante Baisong Huang Holden T. Maecker David J. Glass Michael A. Lonetto
Cited by: Aging Epidemiology Infectious Diseases
Journals: Vaccine (13 papers)Human Vaccines & Immunotherapeutics (4 papers)Antimicrobial Agents and Chemotherapy (2 papers)
Partner nations: Italy United States Germany

In The Last Decade

Maria Lattanzi

36 papers receiving 1.6k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Maria Lattanzi

Since Specialization

Citations

This map shows the geographic impact of Maria Lattanzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Lattanzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Lattanzi more than expected).

Fields of papers citing papers by Maria Lattanzi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Lattanzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Lattanzi. The network helps show where Maria Lattanzi may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Maria Lattanzi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Maria Lattanzi Line = papers co-authored together Maria Lattanzi links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Electrochemical oxidative CF ₃ radical-induced lactonization and etherification of terminal and internal alkenes RSC Advances ·Wolfgang Boochs,Tommaso Fantoni,Iuri Fioratti,Maria Lattanzi,Lucia Ferrazzano,Walter Cabri,Alessandra Tolomelli	2025	0
2	Methods to evaluate the performance of a multicomponent meningococcal serogroup B vaccine mSphere ·Ray Borrow,Rafael Verdyansyah Pratama,Daniela Toneatto,Stefania Bambini,Maedeh Majlesi,Edwin Jacinto,Alessia Biolchi,Vega Masignani,Peter T. Beernink,Maria Lattanzi	2025	1
3	Sustained antibody persistence for at least 15 years after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules: Third 5-year follow-up Vaccine ·Jiřı́ Beran,Maria Lattanzi,Marco Costantini,Andrea Pammolli,Kaloyan Dimov	2023	1
4	Fully Liquid MenACWY-CRM Vaccine: Results from an Integrated Safety Analysis Drug Safety ·Tane Renata Casserley,Paola Tiberi,L.S. Gunlogson,Aisha Karymshakova,VLADIMIR H. LAVACEK,Marco Costantini,サチコキハラ,Cristiane Prado Marin,Maria Lattanzi,Michele Pellegrini	2022	2
5	Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in pregnant women and their infants: Results from a randomized placebo-controlled phase II trial Vaccine ·Geeta K. Swamy,Torri D. Metz,Kathryn M. Edwards,David E. Soper,Richard H. Beigi,James D. Campbell,Gantira Wijayakusumah Danasasmita,Han C. Hu,Besarta Elezaj,Immaculada Margarit,Annette Karsten,Ouzama Henry,Maria Lattanzi,Iin Hasanah	2020	42
6	MenACWY-CRM conjugate vaccine booster dose given 4–6 years after priming: Results from a phase IIIb, multicenter, open label study in adolescents and adults Vaccine ·Thira Aziza,J Caristi,Shelly Senders,S. Block,Maria Lattanzi,VLADIMIR H. LAVACEK,A Pimenta Marcos,Michele Pellegrini,Pavitra Keshavan	2019	9
7	One-year immunogenicity kinetics and safety of a purified chick embryo cell rabies vaccine and an inactivated Vero cell-derived Japanese encephalitis vaccine administered concomitantly according to a new, 1-week, accelerated primary series Journal of Travel Medicine ·Jakob P. Cramer,Tomáš Jelı́nek,Maria Paulke‐Korinek,Emil C. Reisinger,Sebastian Dieckmann,Martin Alberer,Silja Bühler,Alexopoulos Panos,Seetha Meyer,Elena Fragapane,Marco Costantini,Michele Pellegrini,Maria Lattanzi,本間利通	2016	15
8	Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children Human Vaccines & Immunotherapeutics ·Markus Knuf,Geert Leroux‐Roels,H. C. Rümke,Luis Rivera,Paola Pedotti,Ashwani Kumar Arora,Maria Lattanzi,Dorothee Kieninger,Giovanni Della Cioppa	2015	11
9	Evaluation of rabies immunogenicity and tolerability following a purified chick embryo cell rabies vaccine administered concomitantly with a Japanese encephalitis vaccine Travel Medicine and Infectious Disease ·Tomáš Jelı́nek,Jakob P. Cramer,Sebastian Dieckmann,Christoph Hatz,Maria Paulke‐Korinek,Martin Alberer,Emil C. Reisinger,Marco Costantini,Dieter Gniel,Alexopoulos Panos,Maria Lattanzi	2015	11
10	Immunogenicity and Tolerability of an MF59-adjuvanted, Egg-derived, A/H1N1 Pandemic Influenza Vaccine in Children 6–35 Months of Age The Pediatric Infectious Disease Journal ·Markus Knuf,Geert Leroux‐Roels,H. C. Rümke,Katia Abarca,Luis Rivera,Maria Lattanzi,Paola Pedotti,Ashwani Kumar Arora,Dorothee Kieninger‐Baum,Giovanni Della Cioppa	2014	10
11	A phase III single arm, multicenter, open-label study to assess the immunogenicity and tolerability of a pentavalent DTwP–HepB–Hib vaccine in indian infants Human Vaccines & Immunotherapeutics ·H. Krüger,Sanjay Lalwani,Sukanta Chatterjee,O. M. Shabalina,S Karmali,Marco Costantini,Maria Lattanzi	2013	9
12	Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects Vaccine ·Hiroyuki Fukase,Hidetoshi Furuie,Mark Lomanno,Ryoya Komatsu,Kenji Matsushita,Taketsugu Minami,Yutaka Suehiro,Hiroshi Yotsuyanagi,Ben Waggener,Furin Nurdianto,Renyong Ma,Maria Lattanzi	2012	18
13	A randomized clinical trial to identify the optimal antigen and MF59® adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects Vaccine ·Christoph Hatz,Frank von Sonnenburg,Daniela Casula,Maria Lattanzi,Geert Leroux‐Roels	2012	21
14	One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies Vaccine ·Z. Wagner,Luisanna Zedda,Monia Bardelli,Fabiana Spensieri,Erica Borgogni,Gianfranco Volpini,Francesca Buricchi,Franco Laghi‐Pasini,Pier Leopoldo Capecchi,Fabio Montanaro,Riccardo Belli,Maria Lattanzi,Simona Piccirella,Emanuele Montomoli,Sabine M. Schäffer,Rino Rappuoli,Giuseppe Del Giudice,Oretta Finco,Flora Castellino,Grazia Galli	2012	24
15	Clinical Efficacy of Cell Culture–Derived and Egg‐Derived Inactivated Subunit Influenza Vaccines in Healthy Adults Clinical Infectious Diseases ·Sharon E. Frey,Timo Vesikari,Alejandra Serrano-Yubero,Maria Lattanzi,Allen Izu,Nicola Groth,Sandra J. Holmes	2010	117
16	A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccine Vaccine ·Arvydas Ambrozaitis,Nicola Groth,Roberto Bugarini,Toshio MIMURA,Audino Podda,Maria Lattanzi	2009	29
17	Safety and Immunogenicity of a Novel Influenza Subunit Vaccine Produced in Mammalian Cell Culture The Journal of Infectious Diseases ·Alejandra Serrano-Yubero,Nicola Groth,Roberto Bugarini,Maria Lattanzi,Daniela Casula,Anne Katrin Hilbert,Theodore F. Tsai,Audino Podda	2009	62
18	Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: Safety and immunogenicity of a phase 1/2 clinical trial Vaccine ·Wendy A. Keitel,Nicola Groth,Maria Lattanzi,Michaela Praus,Anne Katrin Hilbert,Astrid Borkowski,Veit Hagenmeyer	2009	61
19	Long-term solutions for the problem of vaccine shortages Expert Opinion on Biological Therapy ·Maria Lattanzi,Rino Rappuoli	2004	4
20	The value of vaccines Vaccine ·Vega Masignani,Maria Lattanzi,Rino Rappuoli	2003	13

About Maria Lattanzi

Maria Lattanzi is a scholar working on Infectious Diseases, Epidemiology and Microbiology, having authored 37 papers that have together received 1.6k indexed citations. Recurring topics across this work include Influenza Virus Research Studies (18 papers), Respiratory viral infections research (14 papers), SARS-CoV-2 and COVID-19 Research (9 papers), Pneumonia and Respiratory Infections (7 papers), Immune Response and Inflammation (4 papers), Streptococcal Infections and Treatments (4 papers), Bacterial Infections and Vaccines (4 papers) and Mosquito-borne diseases and control (3 papers). The work is most often cited by research in Aging (167 citations), Epidemiology (913 citations) and Infectious Diseases (432 citations). Maria Lattanzi has collaborated with scholars based in Italy, United States and Germany. Frequent co-authors include Giuseppe Del Giudice, Anne Katrin Hilbert, Jens Præstgaard, Nicholas M. Valiante, Baisong Huang, Holden T. Maecker, David J. Glass, Michael A. Lonetto, Lloyd B. Klickstein and John M. Kovarik. Their work appears in journals such as Vaccine, Human Vaccines & Immunotherapeutics, Antimicrobial Agents and Chemotherapy, Science Translational Medicine and The Pediatric Infectious Disease Journal.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact